



1fw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Scott S. Graves et al.

Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS

Docket No.: 295.061US4

Serial No.: 10/787,067

Filed: February 25, 2004

Due Date: N/A

Examiner: Unknown

Group Art Unit: 1642


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):


- ☒ A return postcard.
- ☒ A Supplemental Information Disclosure Statement (1 pg.), Form 1449 (3 pgs.), and copies of 50 cited documents.


If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number 21186

By: 
Atty: Peter L. Malen
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 31st day of March, 2005.


Name


Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)

S/N 10/787,067

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Scott S. Graves et al.	Examiner:	Unknown
Serial No.:	10/787,067	Group Art Unit:	1642
Filed:	February 25, 2004	Docket:	295.061US4
Title:	HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
SCOTT S. GRAVES ET AL.
By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 371-2110

Date

March 31, 2005

By

Peter L. Malen
Peter L. Malen
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 31st day of March, 2005.

Name

Dawn M. Boyle

Signature


Dawn M. Boyle

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 1 of 3

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Attorney Docket No: 295.061US4

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	2003/0119078	06/26/2003	Graves et al.	01/24/2002
	6,358,710	03/19/2002	Graves et al.	06/09/1997

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	T ²
	EP 0 173 177	03/05/1986	Abstract Only

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	ALBERTS et al., "Molecular Biology of the Cell", Third Edition, Garland Press, New York, NY, 606-608 (1994).
	BENVENUTO et al., "Phytoantibodies": a general vector for the expression of immunoglobulin domains in transgenic plants", <u>Plant Molecular Biology</u> , 17, 865-874 (1991).
	BHATIA et al., "Protein glycosylation: Implications for in vivo functions and therapeutic applications", <u>Advances in Biochemical Engineering / Biotechnology</u> , 64, 155-201 (1999).
	BOLT et al., "The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties", <u>Eur. J. Immunol.</u> , 23, 403-411 (1993).
	BUCKEL et al., "Cloning and nucleotide sequence of heavy- and light-chain cDNAs from a creatine-kinase-specific monoclonal antibody", <u>Gene</u> , 51, 13-19 (1987).
	CUELLO et al., "Detection of substance P in the central nervous system by a monoclonal antibody", <u>PNAS</u> , 76, 3532-3536 (1979).
	DE NEVE et al., "Assembly of an antibody and its derived antibody fragment in Nicotiana and Arabidopsis", <u>Transgenic Research</u> , 2, 227-237 (1993).
	DURING et al., "Synthesis and self-assembly of a functional monoclonal antibody in transgenic Nicotiana tabacum", <u>Plant Molecular Biology</u> , 15, 281-293 (1990).
	FIREK et al., "Secretion of a functional single-chain Fv protein in transgenic tobacco plants and cell suspension cultures", <u>Plant Molecular Biology</u> , 23, 861-870 (1993).
	GOMEZ et al., "Complementation of an Arabidopsis thaliana mutant that lacks complex asparagine-linked glycans with the human cDNA encoding N-acetylglucosaminyltransferase I.", <u>PNAS</u> , 91, 1829-1833 (1994).
	HAN et al., "Possible Relationship Between Coding Recognition Amino Acid Sequence Motif or Residue(s) and Post-Translational Chemical Modification of Proteins", <u>Int. J. Biochem.</u> , 24, 1349-1363 (1992).
	HART et al., "Chapter 10. O-Linked N-Acetylglucosamine: The "Yin-Yang" of Ser/Thr Phosphorylation?", In: <u>Glycoimmunology</u> , Plenum Press, New York, 115-123 (1995).
	HEIN et al., "Evaluation of immunoglobulins from plant cells", <u>Biotechnol. Prog.</u> , 7, 455-461 (1991).
	HESSE et al., "Molecular Cloning and Structural Analysis of a Gene from Zea Mays (L.) Coding for a Putative Receptor for the Plant Hormone Auxin", <u>The EMBO Journal</u> , 8, 2453-2461 (1989).

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 2 of 3

Attorney Docket No: 295.061US4

	HIATT et al., "Production of antibodies in transgenic plants", <u>Nature</u> , 342 , 76-78 (1989).
	HOUNSELL et al., "O-linked protein glycosylation structure and function", <u>Glycoconjugate Journal</u> , 13 , 19-26 (1996).
	HUGHES et al., "Capillary Electrophoretic Examination of Underivatized O-Linked and N-Linked Oligosaccharide Mixtures and Immunoglobulin G Antibody-Released Oligosaccharide Libraries", <u>Journal of Chromatography B</u> , 657 , 315-326 (1994).
	ISAACS et al., "Therapy with Monoclonal Antibodies - An in vivo Model for the Assessment of Therapeutic Potential", <u>The Journal of Immunology</u> , 148 , 3062-3071 (1992).
	JEFFERIS et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcγR)", <u>Molecular Immunology</u> , 27 , 1237-1240 (1990).
	JENKINS et al., "Glycosylation of recombinant proteins: problems and prospects", <u>Enzyme Microb. Technol.</u> , 16 , 354-364 (1994).
	JONES et al., "Replacing the Complementarity-Determining Regions in a Human Antibody With Those of a Mouse", <u>Nature</u> , 321 , 522-525 (1986).
	KABIR et al., "The Binding of Jacalin With Rabbit Immunoglobulin G", <u>Immunological Investigations</u> , 24 , 725-735 (1995).
	KUMPEL et al., "Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity", <u>Hum Antibodies Hybridomas</u> , 5 , 143-151 (1994).
	KUWANO et al., "Glycosylation mutations of serine/threonine-linked oligosaccharides in low-density lipoprotein receptor: indispensable roles of O-glycosylation", <u>Journal of Cell Science</u> , 98 , 131-134 (1991).
	LARRICK et al., "Recombinant antibodies", <u>Hum. Antibod. Hybridomas</u> , 2 , 172-189 (1991).
	LEBECQUE et al., "Immunologic Characterization of Monoclonal Antibodies that Modular Human IgE Binding to the Major Birch Pollen Allergen Bet v1", <u>The Journal of Allergy and Clinical Immunology</u> , 99 , 15 pages (1997).
	LECOMMANDEUR et al., "Glycan Research on Barley, Maize, Oats, and Sorghum Grain Alpha-Amylases: Comparison with Rice alpha-Amylase", <u>Archives of Biochemistry and Biophysics</u> , 278 , 245-250 (1990).
	LEIBIGER et al., "Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding", <u>Biochemical Journal</u> , 338 , 529-538 (1999).
	LEROUGE et al., "N-Glycosylation of Recombinant Pharmaceutical Glycoproteins Produced in Transgenic Plants: Towards an Humanisation of Plant N-Glycans", <u>Current Pharmaceutical Biotechnology</u> , 1 , 347-354 (2000).
	MA et al., "Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants", <u>Eur. J. Immunol.</u> , 24 , 131-138 (1994).
	MA et al., "Generation and assembly of secretory antibodies in plants", <u>Science</u> , 268 , 716-719 (1995).
	MESA et al., "Interferon-gamma receptor extracellular domain-IgG fusion protein produced in Chinese hamster ovary cells as mixture of glycoforms", <u>Journal of Interferon and Cytokine Research</u> , 15 , 309-315 (1995).
	OWEN et al., "Synthesis of a functional anti-phytochrome single-chain Fv protein in transgenic tobacco", <u>Biotechnology</u> , 10 , 790-794 (1992).

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) z Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/787,067

Filing Date February 25, 2004

First Named Inventor Graves, Scott

Group Art Unit 1642

Examiner Name Unknown

Sheet 3 of 3

Attorney Docket No: 295.061US4

	ROUTLEDGE et al., "A humanized monovalent CD3 antibody which can activate homologous complement", <u>Eur. J. Immunol.</u> , 21 , 2717-2725 (1991).
	ROUTLEDGE et al., "The Effect of Aglycosylation on the Immunogenicity of a Humanized Therapeutic CD3 Monoclonal Antibody", <u>Transplantation</u> , 60 , 847-853 (1995).
	RUSSELL, "Feasibility of antibody production in plants for human therapeutic use", <u>Curr Top Microbiol Immunol.</u> , 240 , 119-138 (1999).
	STOGER et al., "Plantibodies: applications, advantages and bottlenecks", <u>Current Opinion in Biotechnology</u> , 13 , 161-166 (2002).
	SWAIN, "Antibodies in plants", <u>TIBTECH</u> , 9 , 107-109 (1991).
	TAKAHASHI et al., "Structure of human immunoglobulin gamma genes: implications for evolution of a gene family", <u>Cell</u> , 29 , 671-679 (1982).
	TALWAR, "Fertility Regulating and Immunotherapeutic Vaccines Reaching Human Trials Stage", <u>Human Reproduction Update</u> , 3 , 301-310 (1997).
	TANIMOTO et al., "Restricted Expression of an Early Myeloid and Monocytic Cell Surface Antigen Defined by Monoclonal Antibody M195", <u>Leukemia</u> , 3 , 339-348 (1989).
	TAVLADORAKI et al., "Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack", <u>Nature</u> , 366 , 469-472 (1993).
	VAN ENGELEN et al., "Coordinate Expression of Antibody Subunit Genes Yields High Levels of Functional Antibodies in Roots of Transgenic Tobacco", <u>Plant Molecular Biology</u> , 26 , 1701-1710 (1994).
	VERHOEYEN et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", <u>Science</u> , 239 , 1534-1536 (1988).
	VON SCHAEWEN et al., "Isolation of a mutant Arabidopsis plant that lacks N-acetyl glucosaminyl transferase I and is unable to synthesize Golgi-modified complex N-linked glycans", <u>Plant Physiol.</u> , 102 , 1109-1118 (1993).
	WILSON, "Glycosylation of proteins in plants and invertebrates", <u>Current Opinion in Structural Biology</u> , 12 , 569-577 (2002).
	WORMALD et al., "Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides", <u>Biochemistry</u> , 36 , 1370-1380 (1997).
	WRIGHT et al., "Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1", <u>J. Exp. Med.</u> , 180 , 1087-1096 (1994).
	YOUINGS et al., "Site-Specific Glycosylation of Human Immunoglobulin G is Altered in Four Rheumatoid Arthristis Patients", <u>Biochem. J.</u> , 314 , 621-630 (1996).

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached